Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18344429rdf:typepubmed:Citationlld:pubmed
pubmed-article:18344429lifeskim:mentionsumls-concept:C1140680lld:lifeskim
pubmed-article:18344429lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:18344429lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:18344429lifeskim:mentionsumls-concept:C0332161lld:lifeskim
pubmed-article:18344429lifeskim:mentionsumls-concept:C0178638lld:lifeskim
pubmed-article:18344429lifeskim:mentionsumls-concept:C0210657lld:lifeskim
pubmed-article:18344429pubmed:issue4lld:pubmed
pubmed-article:18344429pubmed:dateCreated2008-3-31lld:pubmed
pubmed-article:18344429pubmed:abstractTextFolate-based radiopharmaceuticals can be used as imaging agents and for potential radiotherapy of folate receptor (FR)-positive malignant tissue (e.g., ovarian carcinomas). However, substantial FR expression in the kidneys results in undesired renal retention of radioactivity. Recently, we found that the preinjection of an antifolate significantly improved tumor selectivity of organometallic 99mTc-radiofolates in mice. The aim of this study was to corroborate the effect of pemetrexed with the clinically tested 111In-DTPA-folate (DTPA is diethylenetriaminepentaacetic acid) in a human ovarian cancer xenografted mouse model.lld:pubmed
pubmed-article:18344429pubmed:languageenglld:pubmed
pubmed-article:18344429pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:citationSubsetIMlld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18344429pubmed:statusMEDLINElld:pubmed
pubmed-article:18344429pubmed:monthAprlld:pubmed
pubmed-article:18344429pubmed:issn0161-5505lld:pubmed
pubmed-article:18344429pubmed:authorpubmed-author:KrenningEric...lld:pubmed
pubmed-article:18344429pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:18344429pubmed:authorpubmed-author:SchibliRogerRlld:pubmed
pubmed-article:18344429pubmed:authorpubmed-author:MüllerCristin...lld:pubmed
pubmed-article:18344429pubmed:issnTypePrintlld:pubmed
pubmed-article:18344429pubmed:volume49lld:pubmed
pubmed-article:18344429pubmed:ownerNLMlld:pubmed
pubmed-article:18344429pubmed:authorsCompleteYlld:pubmed
pubmed-article:18344429pubmed:pagination623-9lld:pubmed
pubmed-article:18344429pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:meshHeadingpubmed-meshheading:18344429...lld:pubmed
pubmed-article:18344429pubmed:year2008lld:pubmed
pubmed-article:18344429pubmed:articleTitlePemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer.lld:pubmed
pubmed-article:18344429pubmed:affiliationDepartment of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. cristina.mueller@psi.chlld:pubmed
pubmed-article:18344429pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18344429lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18344429lld:pubmed